As exemplified in the present study, genetic polymorphisms/mutations and fine balances among NRF2, KEAP1, MDM2, p53, p21WAF1/cip1 and other genes are likely to contribute to the progression of cancer and, consequently, the prognosis of cancer patients. This evidence concerns the gene TP53 and cancer.